- Brand Name : Daxxify
- Drug Class : Acetylcholinesterase Inhibitors, Central, Neuromuscular Blockers, Depolarizing
- Medical Author : Dr. Vinod Katiboina, Pharm. D.
- Medical Reviewer : Divya Jacob, Pharm. D.
- _eael_post_view_count : 6
What Is DaxibotulinumtoxinA and How Does It Work?
DaxibotulinumtoxinA is a prescription medication used for temporary improvement in appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity.
- DaxibotulinumtoxinA is available under the following different brand names: Daxxify, daxibotulinumtoxinA-lanm
What Are Side Effects Associated with Using DaxibotulinumtoxinA?
Common side effects of DaxibotulinumtoxinA include:
Serious side effects of DaxibotulinumtoxinA include:
- hives
- difficulty breathing
- swelling of the face, lips, tongue, or throat
- dizziness
Rare side effects of DaxibotulinumtoxinA include:
- none
Seek medical care or call 911 at once if you have the following serious side effects:
- Severe headache, confusion, slurred speech, arm or leg weakness, trouble walking, coordination loss, unsteady, very stiff muscles, high fever, profuse sweating, or tremors
- Serious eye symptoms such as sudden vision loss, blurred vision, tunnel vision, eye pain or swelling, or seeing halos around lights
- Serious heart symptoms include fast, irregular, or pounding heartbeats; fluttering in the chest; shortness of breath; sudden dizziness, light-headedness, or passing out
This is not a complete list of side effects and other serious side effects or health problems that may occur because of the use of this drug. Call your doctor for medical advice about serious side effects or adverse reactions. You may report side effects or health problems to FDA at 1-800-FDA-1088.
What Are the Dosages of DaxibotulinumtoxinA?
Adult dosage
Injection, lyophilized powder for reconstitution
- 50 units/single-dose vial
- 100 units/single-dose vial
Glabellar lines
Adult dosage
- 0.1 mL (8 units) IM each into 5 sites, for a total dose of 40 units.
- Injections in each corrugator muscle and 1 injection in the procerus muscle.
- Administer no more frequently than every 3 months.
Dosage Considerations – Should be Given as Follows:
- See “Dosages”